Planning on attending BIO in San Diego?  Don’t miss our expert panel discussion on the exhibition floor in the BioProcess Theater on Wednesday, June 24, from 11 am to 12 pm.

Panel Discussion Title – Integrated CLD: Manufacturability to GMP-Ready by Design

We’re entering an exciting new era of drug development, defined by increasingly sophisticated biologics, including bispecific antibodies and fusion proteins, as well as rapidly emerging bioconjugate modalities, such as antibody-oligonucleotide conjugates (AOCs). These next-generation therapeutics are expanding what’s possible for patients, enabling more precise targeting, novel mechanisms of action, and access to disease biology that has historically been difficult to address.

Across these modalities, Abzena’s experience points to a consistent theme: scientific promise alone is not enough to create a successful medicine. As molecular formats become more complex, developability and manufacturability must be considered from the earliest stages of discovery and development. Candidates need to demonstrate not only compelling biology but also the stability, productivity, product quality, analytical profile, and process robustness required to progress efficiently through development and into reliable clinical and commercial supply.

A robust and capable cell line development platform is therefore a critical enabler of the next generation of biologics. Such platforms, like AbZelectPRO™, support diverse and challenging molecular architectures, deliver high-producing and genetically stable cell lines, and provide a strong foundation for scalable manufacturing. By integrating cell line engineering, developability assessment, and manufacturability insight, drug developers can increase the probability of technical success, accelerate timelines, and ensure that innovative biologics can ultimately be manufactured at the quality and scale required for patients.

In this panel discussion, experts from Abzena &Syner-G BioPharma Group will discuss how an integrated approach to cell line development and developability can help drug developers navigate this new era of biologics with greater confidence and speed.

Panelists Include

• Campbell Bunce, PhD – CSO at Abzena
• Scott Rudge, PhD – Founder & Principal Consultant at Syner-G Biopharma
• John Gill – VP & Scientific Leader of Cell Line Development

Access the Full Theater Agenda